American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
MIAMI, March 03, 2017 -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced that it will host a conference call to update investors on the Company’s product commercialization and drug development progress on Thursday, March 9, 2017 at 10:30 a.m. Eastern Time (ET).
|
|||
The conference call will be available to interested parties by dialing 1-877-883-0383 from the U.S. or 1-412-902-6506 from international locations, participant entry number for all 9649925.
A replay of the conference call will be available beginning on Tuesday, March 14, 2017 through Tuesday, March 21, 2017, by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the replay access code 10102781. After Tuesday, March 21, 2017, the replay of the call will be available on the Company’s website at www.fhcinvestor.com.
About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway. The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipes, which are a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
- The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business. This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.
More information about The Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org. For corporate and investor-related information about the Company, please visit www.FHCinvestor.com.
Contact: Kevin Gilbert: 312-366-2633
